Comparative Pharmacology
Head-to-head clinical analysis: A HYDROCORT versus HYDROCORTISONE SODIUM SUCCINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A HYDROCORT versus HYDROCORTISONE SODIUM SUCCINATE.
A-HYDROCORT vs HYDROCORTISONE SODIUM SUCCINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.
Hydrocortisone sodium succinate is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, immunosuppressive, and anti-stress responses. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.
100–500 mg IV or IM every 2–6 hours, as needed; typical initial dose 100–250 mg IV bolus followed by 100–250 mg IV every 4–6 hours for acute conditions.
None Documented
None Documented
Terminal half-life: 1.5-2 hours (cortisol); clinical effect persists 8-12 hours due to glucocorticoid receptor binding
1.5-2 hours (plasma terminal); biological half-life 8-12 hours (due to intracellular effects), requiring q6-8h dosing in adrenal insufficiency
Renal (primarily as metabolites, <1% unchanged); biliary/fecal (<5%)
Renal (90-95% as metabolites, <5% unchanged); biliary/fecal <5%
Category C
Category D/X
Corticosteroid
Corticosteroid